Aptorum Group Limited

1.39+0.0800+6.11%Vol 310.34K1Y Perf -58.81%
Jun 24th, 2022 15:59 DELAYED
BID1.07 ASK1.44
Open1.28 Previous Close1.31
Pre-Market- After-Market-
 - -  - -%
Target Price
22.00 
Analyst Rating
— — 0.00
Potential %
1.48K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★+     48.28
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★+     63.44
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
21.52 
Earnings Rating
Neutral
Market Cap49.63M 
Earnings Date
29th Jul 2022
Alpha-0.03 Standard Deviation0.28
Beta0.13 

Today's Price Range

1.281.60

52W Range

0.85533.34

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
20.87%
1 Month
26.36%
3 Months
1.46%
6 Months
-16.77%
1 Year
-58.81%
3 Years
-94.71%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
APM1.390.08006.11
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date29th Jul 2022
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume310.34K
Shares Outstanding35.70K
Shares Float8.13M
Trades Count751
Dollar Volume449.01K
Avg. Volume92.13K
Avg. Weekly Volume66.56K
Avg. Monthly Volume104.59K
Avg. Quarterly Volume105.25K

Aptorum Group Limited (NASDAQ: APM) stock closed at 1.39 per share at the end of the most recent trading day (a 6.11% change compared to the prior day closing price) with a volume of 310.34K shares and market capitalization of 49.63M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 39 people. Aptorum Group Limited CEO is Ian Huen.

The one-year performance of Aptorum Group Limited stock is -58.81%, while year-to-date (YTD) performance is -7.33%. APM stock has a five-year performance of %. Its 52-week range is between 0.8553 and 3.34, which gives APM stock a 52-week price range ratio of 21.52%

Aptorum Group Limited currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 1.74, a price-to-sale (PS) ratio of 9.89, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -75.75%, a ROC of -11.91% and a ROE of -76.55%. The company’s profit margin is -%, its EBITDA margin is -306.00%, and its revenue ttm is $1.54 Million , which makes it $0.12 revenue per share.

Of the last four earnings reports from Aptorum Group Limited, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Aptorum Group Limited’s next earnings report date is 29th Jul 2022.

The consensus rating of Wall Street analysts for Aptorum Group Limited is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Aptorum Group Limited stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aptorum Group Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aptorum Group Limited has a Buy technical analysis rating based on Technical Indicators (ADX : 19.66, ATR14 : 0.13, CCI20 : 197.01, Chaikin Money Flow : -0.07, MACD : 0.03, Money Flow Index : 88.74, ROC : 10.32, RSI : 62.32, STOCH (14,3) : 61.12, STOCH RSI : 1.00, UO : 51.71, Williams %R : -38.88), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aptorum Group Limited in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Aptorum Group Limited

Aptorum Group Ltd is a pharmaceutical company. It is engaged in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The firm is also seeking therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.

CEO: Ian Huen

Telephone: +44 2080929299

Address: 17 Hanover Square, London W1S 1BN, , GB

Number of employees: 39

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

71%29%

Bearish Bullish

65%35%

News

Stocktwits